Engineering a solution for allogeneic CAR-T rejection.
作者信息
Amini Leila, Peter Lena, Schmueck-Henneresse Michael
机构信息
Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Experimental Immunotherapy, Augustenburger Platz 1, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT) at Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Experimental Immunotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
出版信息
Mol Ther. 2024 Oct 2;32(10):3204-3206. doi: 10.1016/j.ymthe.2024.08.025. Epub 2024 Sep 11.
Abstract
摘要
相似文献
1
Engineering a solution for allogeneic CAR-T rejection.构建一种针对异体嵌合抗原受体T细胞（CAR-T）排斥反应的解决方案。
Mol Ther. 2024 Oct 2;32(10):3204-3206. doi: 10.1016/j.ymthe.2024.08.025. Epub 2024 Sep 11.
2
Cars pick up another passenger: Organ transplantation.
Hum Immunol. 2025 Jan;86(1):111180. doi: 10.1016/j.humimm.2024.111180. Epub 2024 Nov 26.
3
Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.实体瘤和年龄相关病症中的衰老细胞裂解性嵌合抗原受体T细胞
Mol Ther. 2020 Oct 7;28(10):2108-2110. doi: 10.1016/j.ymthe.2020.08.011. Epub 2020 Aug 25.
4
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造：创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
5
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.利用细胞和基因组修饰技术来生成改良的“现货”CAR T 和 CAR NK 细胞。
Front Immunol. 2020 Aug 7;11:1965. doi: 10.3389/fimmu.2020.01965. eCollection 2020.
6
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
7
Advances in off-the-shelf CAR T-cell therapy.现成的嵌合抗原受体T细胞疗法的进展。
Clin Adv Hematol Oncol. 2019 Mar;17(3):155-157.
8
Using TCR-CAR dual signaling for precise cancer targeting.利用TCR-CAR双信号进行精准癌症靶向治疗。
Trends Immunol. 2025 Jun;46(6):435-437. doi: 10.1016/j.it.2025.04.007. Epub 2025 May 13.
9
CAR-ving away OX40L with engineered T.利用工程化 T 细胞 CAR-ving 掉 OX40L
Sci Immunol. 2024 Nov;9(101):eadu0983. doi: 10.1126/sciimmunol.adu0983. Epub 2024 Nov 1.
10
[Development of allogeneic CAR T-cells].[同种异体嵌合抗原受体T细胞的开发]
Bull Cancer. 2021 Oct;108(10S):S73-S80. doi: 10.1016/j.bulcan.2021.01.025.
本文引用的文献
1
Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells.免疫抑制剂疗法可避免同种异体 FKBP1A 敲除 CAR-T 细胞的排斥反应。
Mol Ther. 2024 Oct 2;32(10):3485-3503. doi: 10.1016/j.ymthe.2024.06.022. Epub 2024 Sep 1.
2
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.CD19 CAR T 细胞疗法治疗自身免疫性疾病 - 附随访的病例系列。
N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917.
3
Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells.环孢素 A 耐药的 CAR-T 细胞在同种异体细胞存在的情况下介导抗肿瘤免疫。
Nat Commun. 2023 Dec 20;14(1):8491. doi: 10.1038/s41467-023-44176-0.
4
Complete remission of aggressive Epstein-Barr virus-positive diffuse large B-cell lymphoma following withdrawal of tacrolimus and low-dose anticancer drugs.停用他克莫司和低剂量抗癌药物后侵袭性爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤完全缓解
EJHaem. 2023 Aug 8;4(4):1160-1163. doi: 10.1002/jha2.761. eCollection 2023 Nov.
5
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.B 细胞非霍奇金淋巴瘤肿瘤内调节性 T 细胞的异质性。
Blood Adv. 2023 Dec 12;7(23):7216-7230. doi: 10.1182/bloodadvances.2023010158.
6
Post-infusion CAR T cells identify patients resistant to CD19-CAR therapy.输注后嵌合抗原受体 T 细胞可鉴定出对 CD19-CAR 治疗产生耐药的患者。
Nat Med. 2022 Sep;28(9):1860-1871. doi: 10.1038/s41591-022-01960-7. Epub 2022 Sep 12.
7
Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry.通过液质联用技术对接受肾移植患者进行长期他克莫司和雷帕霉素治疗的 T 细胞群体进行深度表型分析。
Clin Transl Med. 2021 Nov;11(11):e629. doi: 10.1002/ctm2.629.
8
Immunogenicity of CAR T cells in cancer therapy.嵌合抗原受体 T 细胞在癌症治疗中的免疫原性。
Nat Rev Clin Oncol. 2021 Jun;18(6):379-393. doi: 10.1038/s41571-021-00476-2. Epub 2021 Feb 25.
9
CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients.CRISPR-Cas9 编辑的他克莫司耐药抗病毒 T 细胞用于移植受者的高级过继免疫治疗。
Mol Ther. 2021 Jan 6;29(1):32-46. doi: 10.1016/j.ymthe.2020.09.011. Epub 2020 Sep 8.
10
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.细胞因子 IL-36γ 可改善 CAR T 细胞功能并诱导内源性抗肿瘤反应。
Leukemia. 2021 Feb;35(2):506-521. doi: 10.1038/s41375-020-0874-1. Epub 2020 May 23.
Zotero 插件